Evidence map›Paper›PMID 42020444›Full record

ArticleNature communications2026

An in vitro approach for simulating divergent Golgi O-glycosylation of tumor-associated MUC1 from normal MUC1.

Abdullateef Nashed, Kyllen Dilsook, Tharindu Senapathi, Kevin J Naidoo

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abdullateef NashedScientific Computing Research Unit, University of Cape Town, Rondebosch, South Africa.ORCID 0009-0008-5672-4688
Kyllen DilsookScientific Computing Research Unit, University of Cape Town, Rondebosch, South Africa.
Tharindu SenapathiScientific Computing Research Unit, University of Cape Town, Rondebosch, South Africa.ORCID 0000-0002-3277-4022
Kevin J NaidooScientific Computing Research Unit, University of Cape Town, Rondebosch, South Africa. kevin.naidoo@uct.ac.za.ORCID 0000-0002-9898-3708

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide O-glycosylation relies on the coordinated action of glycosyltransferases across the endoplasmic reticulum (ER) and Golgi apparatus. However, the molecular mechanisms driving aberrant glycosylation in cancer remain poorly understood. Here we show an in vitro one-pot synthetic biology approach that simulates divergent glycosylation pathways to map the synthesis of mucin 1 (MUC1) tumor-associated antigens. By modeling the cancer-associated relocation of initiation enzymes (GALNTs) to the ER, we demonstrate that this spatial shift leads to complete GalNAc (Tn antigen) occupancy. This occurs because ER localization extends reaction times and prevents inhibition by downstream Golgi enzymes. Furthermore, combined kinetic and computer reaction dynamic simulations reveal that ST6GALNAC1 exclusively drives α-2-6 sialylation, with a strict preference for the T13 site on fully glycosylated MUC1. This suggests that cancer-associated sTn upregulation is directly linked to T13 occupancy. Ultimately, this systems modeling approach decodes the enzyme localization and substrate specificities fundamental to tumourigenesis.

Indexed as

Golgi ApparatusMucin-1Antigens, Tumor-Associated, Carbohydratebeta-D-Galactoside alpha 2-6-SialyltransferaseEndoplasmic ReticulumGlycosylationHumansKineticsSialyltransferasesAntigens, Tumor-Associated, Carbohydratebeta-D-Galactoside alpha 2-6-SialyltransferaseMUC1 protein, humanMucin-1SialyltransferasesTn antigen

Identifiers

PMID42020444
PMCPMC13103387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.